Skip to main content
. Author manuscript; available in PMC: 2021 Jul 11.
Published in final edited form as: Nat Microbiol. 2021 Jan 11;6(3):401–412. doi: 10.1038/s41564-020-00832-5

Extended Data Fig. 5. Inhibition of Pak1 diminishes NLRP3 activation by Nigericin.

Extended Data Fig. 5

(a, b) BMDMs isolated from C57BL/6J mice were treated with MCC950 (1 μM) or IPA-3 (5 μM) for 45 min prior to Nigericin (5 μM) treatment for 30 min. Supernatan and cell lysates were analyzed by (a) immunoblot and (b) supernatants were analyzed for LDH release (n=3 biologically independent experiments). Statistical analyses were performed using a two-tailed nonparametric Mann Whitney test. n=3 biologically independent samples were analyzed. (c) BMDMs isolated from C57BL/6J mice were treated for 72 h with non-targeting or Pak1 -targeting siRNA before treatment with Nigericin (5 μM) for 30 min. Supernatants and cell lysates were analyzed by immunoblot. The numbers on the side of the immunoblots indicate molecular weight (kDa). Experiments were repeated at least three times, and representative data are shown. Data are expressed as the mean ± SEM.